Thorleif Krarup proposed as new Chairman of Nutri Pharma ASA
25.01.2010 - Thorleif Krarup to be proposed as new Chairman of the Board in Extraordinary Shareholders Meeting to be held on February 12
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
Thorleif Krarup to be proposed as new Chairman of the Board in Extraordinary
Shareholders Meeting to be held on February 12.
With reference to stock exchange release of 22 February regarding Extraordinary
Shareholders Meeting on February 12, Nutri Pharma informs that the board of
Nutri Pharma will propose to the shareholders in the extraordinary shareholders
meeting of 12 February that Thorleif Krarup be elected as Chairman of the Board
of the company, conditioned upon and with effect from the completion of the
Bionor Immuno offer. Mr. Krarup, who is a Danish citizen residing in Denmark, is
inter alia Deputy Chairman of the Boards of H. Lundbeck A/S (pharmaceuticals),
Alk Abello A/S (allergy
treatment/pharmaceuticals) and LFI A/S (investment company holding 72% of H.
Lundbeck), Member of the Board of Group 4 Securicor Plc (security and cash
services, listed in London), Member of the Board Lundbeckfonden (foundation),
and Member of the Board of The Crown Prince Frederik Fond (foundation). Thorleif
Krarup has between 1992 and 2000 served as Group Chief Executive and Chairman of
the Executive Board, Unidanmark and Unibank.
He was Deputy Chief Executive Officer, Nordea AB, Stockholm in 2000-2001, Group
Chief Executive and Chairman of the Executive Board, Nordea, 2001 - 2002, and in
2002 - 2003 Senior Vice President Business development, Nordea
AB, København. From 2003 - 2009 he was a Board Member and Senior Advisor
to Nordic Capital. He has since 2003 acted as a consultant to international
investment companies and banks.
Mr. Krarup intends to subscribe for shares in the contemplated Private Placement
of minimum 50 MNOK for an amount equalling EUR 100.000. Further, Lars Høie,
owner of 52 mill. shares in Nutri Pharma, has agreed to sell 3 million shares to
mr Krarup at a price of NOK 3,10 per share (based on price of the NUT shares on
21 February), conditioned upon the completion of the Bionor Immuno offer and the
Private Placement. The 3 million shares will be subject to lock-up for 4 years,
however so that 1 million shares can be sold in two years and an additional 1
million shares after the third anniversary of the agreement.
FOR FURTHER INFORMATION:
Trond Syvertsen, CEO